Dow Jones Newswires: Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints

The company said it would keep working on novel diagnostics and treatments for Alzheimer’s and said it would present at the Clinical Trials on Alzheimer’s Disease Conference.